[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335574-105":59,"doc-detail-335574-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","identification-of-functional-immune-biomarkers-in-breast-cancer-patients","Identification of Functional Immune Biomarkers in Breast Cancer Patients","","Cancer immunotherapy is increasingly used as a personalized option, yet breast cancer responses remain limited, partly attributed to cold, immune-excluded, or immune-desert tumor environments. Natural killer T (NKT) cells support cancer immune surveillance and are decreased in affected patients. This study tests NKT cells as surrogate indicators of immune function by combining NKT stimulation with artificial antigen-presenting cells and quantitative real-time PCR for IFN-γ, revealing reduced circulating NKT percentages but preserved function in most patients.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/identification-of-functional-immune-biomarkers-in-breast-cancer-patients/335574/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/identification-of-functional-immune-biomarkers-in-breast-cancer-patients/335574.png","ImageObject",300,407,{"name":92,"@type":93},"Seraphina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":81},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What biomarker approach does the study use to evaluate immune function in breast cancer patients?","Question",{"text":112,"@type":113},"The study develops a quantitative method that stimulates NKT cells with artificial antigen-presenting cells followed by quantitative real-time PCR measurement of IFN-γ.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is observed about NKT cells in breast cancer patients compared with healthy donors?",{"text":117,"@type":113},"Circulating NKT cells are significantly reduced in breast cancer patients, but most patients still retain functional NKT responses.",{"name":119,"@type":110,"acceptedAnswer":120},"How do functional differences relate to NKT cell numbers in patient groups?",{"text":121,"@type":113},"Patients with highly functional NKT cells and those with little or no IFN-γ induction show no significant difference in NKT cell number, indicating that functional loss is more important than physical loss of this subpopulation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335574,1792315964,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":81,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","Article  \nIdentification of Functional Immune Biomarkers in Breast Cancer Patients  \nRoshanak Derakhshandeh 1, Yuyi Zhu 1, Junxin Li 1, Danubia Hester 1, Rania Younis 2,3,†, Rima Koka 3,4, Laundette P. Jones 3,5, Wenji Sun 1, Olga Goloubeva 3,5, Katherine Tkaczuk 3, Joshua Bates 1, Jocelyn Reader 3,6,7 and Tonya J. Webb 1,3, *  \nCitation: Derakhshandeh, R.; Zhu, Y.; Li, J.; Hester, D.; Younis, R.; Koka, R.; Jones, L.P.; Sun, W.; Goloubeva, O.; Tkaczuk, K.; et al. Identification of Functional Immune Biomarkers in Breast Cancer Patients. Int. J. Mol. Sci. 2024, 25, 12309. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/ijms252212309](10.3390/ijms252212309)  \nAcademic Editor: Andrew R. Green  \nReceived: 21 September 2024  \nRevised: 8 November 2024  \nAccepted: 11 November 2024  \nPublished: 16 November 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA; [roshanak.derakhshandeh@gunet.georgetown.edu](roshanak.derakhshandeh@gunet.georgetown.edu) (R.D.); [yuyizhu1@som.umaryland.edu](yuyizhu1@som.umaryland.edu) (Y.Z.); [celine.junxin@gmail.com](celine.junxin@gmail.com) (J.L.); [danubia.hester@usoncology.com](danubia.hester@usoncology.com) (D.H.); [wsun@som.umaryland.edu](wsun@som.umaryland.edu) (W.S.); [joshua.bates@umaryland.edu](joshua.bates@umaryland.edu) (J.B.)  \n2 Department of Oncology and Diagnostic Sciences, University of Maryland School of Dentistry, Baltimore, MD 21201, USA; [rania.younis@gmail.com](rania.younis@gmail.com)  \n3 Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Baltimore, MD 21201, USA; [mkoka@som.umaryland.edu](mkoka@som.umaryland.edu) (R.K.); [lpjones@som.umaryland.edu](lpjones@som.umaryland.edu) (L.P.J.); [ogoloubeva@som.umaryland.edu](ogoloubeva@som.umaryland.edu) (O.G.); [ktkaczuk@umm.edu](ktkaczuk@umm.edu) (K.T.); [jreader@umes.edu](jreader@umes.edu) (J.R.)  \n4 Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA  \n5 Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA  \n6 Department of Pharmaceutical Sciences, University of Maryland Eastern Shore, Princess Anne, MD 21853, USA  \n7 Department of Obstetrics, Gynecology and Reproductive Sciences, University of Maryland School of Medicine, Baltimore, MD 21201, USA  \n* Correspondence: [twebb@som.umaryland.edu](twebb@som.umaryland.edu)  \n† Current address: Department of Oral Pathology, Faculty of Dentistry, Alexandria University, Alexandria 21563, Egypt.  \nAbstract: Cancer immunotherapy has emerged as an effective, personalized treatment for certain patients, particularly for those with hematological malignancies. However, its efficacy in breast cancer has been marginal—perhaps due to cold, immune-excluded, or immune-desert tumors. Natural killer T (NKT) cells play a critical role in cancer immune surveillance and are reduced in cancer patients. Thus, we hypothesized that NKT cells could serve as a surrogate marker for immune function. In order to assess which breast cancer patients would likely benefit from immune cell-based therapies, we have developed a quantitative method to rapidly assess NKT function using stimulation with artificial antigen presenting cells followed by quantitative real-time PCR for IFN-γ . We observed a significant reduction in the percentage of circulating NKT cells in breast cancer patients, compared to healthy donors; however, the majority of patients had functional NKT cells. When we compared BC patients with highly functional NKT cells, as indicated b","cbCaij7tahAP0GF8","https://ap.wps.com/l/cbCaij7tahAP0GF8","pdf",4284499,18,"English","# Introduction\n## Methods and assessment of NKT function\n## NKT cell frequency and functional responses\n## Tumor microenvironment markers and immune gene signatures\n## Mechanisms of immune suppression and lipid-targeting interventions","[{\"question\":\"What biomarker approach does the study use to evaluate immune function in breast cancer patients?\",\"answer\":\"The study develops a quantitative method that stimulates NKT cells with artificial antigen-presenting cells followed by quantitative real-time PCR measurement of IFN-γ.\"},{\"question\":\"What is observed about NKT cells in breast cancer patients compared with healthy donors?\",\"answer\":\"Circulating NKT cells are significantly reduced in breast cancer patients, but most patients still retain functional NKT responses.\"},{\"question\":\"How do functional differences relate to NKT cell numbers in patient groups?\",\"answer\":\"Patients with highly functional NKT cells and those with little or no IFN-γ induction show no significant difference in NKT cell number, indicating that functional loss is more important than physical loss of this subpopulation.\"}]","Identification of Functional Immune Biomarkers in Breast Cancer Patients | PDF",1790011474,45]